SCHEMBL1675417

SCHEMBL1675417

c1ccc(-c2nc3ncccc3o2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.73
RAB9A P51151 9/20 0.73
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 6/20 0.59
HPGD P15428 5/20 0.59
HSD17B10 Q99714 5/20 0.59
GAA P10253 4/20 0.59
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 5/20 0.58
TP53 P04637 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
ALOX12 P18054 1/20 0.57
HAVCR2 Q8TDQ0 1/20 0.57
POLB P06746 2/20 0.52
PKM P14618 1/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12910353 0.91 NPC1 (0.81) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL13703258 0.87 NPC1 (0.66) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL12910362 0.86 NPC1 (0.77) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL12910367 0.86 NPC1 (0.73) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL14225131 0.85 NPC1 (0.58) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL941615 0.84 NPC1 (0.71) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL9155132 0.84 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL12910371 0.84 NPC1 (0.75) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2249527 0.84 RAB9A (0.71) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL17391943 0.84 NPC1 (0.71) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140135305-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2014-05-15 US claimed
US-20110086833-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. 2011-04-14 US claimed
WO-2009151546-A2 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2009-12-17 WO claimed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-20230250118-A1 ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF Beijing Summer Sprout Technology Co., Ltd. (CN) 2023-08-10 US disclosed
US-20220402877-A1 ELECTROLUMINESCENT DEVICE Beijing Summer Sprout Technology Co., Ltd. (CN) 2022-12-22 US disclosed
CN-114149380-A Novel preparation method of 2-aryl benzoxazole series compounds 江西师范大学 2022-03-08 CN disclosed
US-20210380618-A1 ORGANIC LIGHT EMITTING MATERIAL Beijing Summer Sprout Technology Co., Ltd. (CN) 2021-12-09 US disclosed
US-9695193-B2 Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-07-04 US disclosed
US-9695193-B2 Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-07-04 US disclosed
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases PTC THERAPEUTICS, INC. (US) 2008-10-30 US disclosed
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases PTC THERAPEUTICS, INC. (US) 2008-10-30 US disclosed
US-20080138656-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2008-06-12 US disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
WO-2007117438-A2 METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH PTC THERAPEUTICS, INC. (US) 2007-10-18 WO disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed
US-5061713-A NO ANTIINFLAMMATORY ACTIVITY SCIENCE ET ORGANIZATION (FR) 1991-10-29 US disclosed
US-4131677-A Anti-inflammatory oxazolo [5,4-b]pyridines MERCK & CO., INC. (US) 1978-12-26 US disclosed
US-4038396-A ANTIPYRETICS, ANALGESICS MERCK & CO., INC. (US) 1977-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A NPC1 2808/4885RAB9A 657/4885KDM4E 489/4885
US-20110086833-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, NSUN2, SNRPB2 NPC1 1960/4885RAB9A 2958/4885KDM4E 2454/4885
US-20220402877-A1 ELECTROLUMINESCENT DEVICE MCOLN2, MCOLN1, LDHB NPC1 2599/4885RAB9A 881/4885KDM4E 1211/4885
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF AHR, ORAI3, WNT3 NPC1 2396/4885RAB9A 3127/4885KDM4E 3942/4885
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases UPF1, NSUN2, RNMT NPC1 971/4885RAB9A 3411/4885KDM4E 1079/4885
US-20230250118-A1 ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF CRY1, LEF1, PIEZO1 NPC1 4075/4885RAB9A 834/4885KDM4E 743/4885
US-20140135305-A1 METHODS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, NSUN2, SNRPB2 NPC1 1960/4885RAB9A 2958/4885KDM4E 2454/4885
US-20080138656-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CRY1, ORC3, OXER1 NPC1 3514/4885RAB9A 2099/4885KDM4E 3552/4885
US-20210380618-A1 ORGANIC LIGHT EMITTING MATERIAL LEF1, CRY1, CYBA NPC1 2676/4885RAB9A 1103/4885KDM4E 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.